{"id":4013,"date":"2025-06-27T12:29:23","date_gmt":"2025-06-27T09:29:23","guid":{"rendered":"https:\/\/dmdwarrior.com\/?p=4013"},"modified":"2025-06-27T12:29:24","modified_gmt":"2025-06-27T09:29:24","slug":"entrada-therapeutics-begins-clinical-trials-in-europe-for-exon-44-and-exon-45-skipping-therapies","status":"publish","type":"post","link":"https:\/\/dmdwarrior.com\/tr\/entrada-therapeutics-begins-clinical-trials-in-europe-for-exon-44-and-exon-45-skipping-therapies\/","title":{"rendered":"Entrada Therapeutics, Avrupa'da Ekzon 44 ve Ekzon 45 Atlama Terapileri i\u00e7in Klinik Denemelere Ba\u015fl\u0131yor"},"content":{"rendered":"<p class=\"wp-block-paragraph\">Entrada Therapeutics, Ekzon 44 ve Ekzon 45'i hedef alan yenilik\u00e7i ekzon atlama tedavileri i\u00e7in Avrupa'da klinik \u00e7al\u0131\u015fmalar\u0131 resmen ba\u015flatt\u0131. Bu, Duchenne kas distrofisi (DMD) tedavisinde \u00f6nemli bir d\u00f6n\u00fcm noktas\u0131 oldu.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Bu ara\u015ft\u0131rma terapileri, distrofin \u00fcretimini geri kazand\u0131rma ve klinik sonu\u00e7lar\u0131 iyile\u015ftirme amac\u0131yla DMD hastalar\u0131ndaki belirli genetik mutasyonlar\u0131 ele almak \u00fczere tasarlanm\u0131\u015ft\u0131r. Bu denemelerin ba\u015flamas\u0131, Entrada&#039;nin hassas genetik t\u0131bb\u0131 ilerletme ve nadir n\u00f6rom\u00fcsk\u00fcler hastal\u0131klar i\u00e7in yeni tedavilere k\u00fcresel eri\u015fimi geni\u015fletme konusundaki kararl\u0131l\u0131\u011f\u0131n\u0131 vurgulamaktad\u0131r. \u2013 Daha Fazlas\u0131n\u0131 Okuyun: <a href=\"https:\/\/dmdwarrior.com\/tr\/what-is-exon-skipping-and-how-does-it-work\/\" target=\"_blank\" rel=\"noreferrer noopener\">Ekzon Atlama Nedir ve Nas\u0131l \u00c7al\u0131\u015f\u0131r?<\/a> \u2013<\/p>\n\n\n\n<div class=\"wp-block-rank-math-toc-block\" id=\"rank-math-toc\"><h2>\u0130\u00e7indekiler<\/h2><nav><ul><li><a href=\"#entrada-exon-44-skipping-nct-07037862\">Entrada Ekzon 44 Atlama \u2013 NCT07037862 \u2013<\/a><\/li><li><a href=\"#entrada-exon-45-skipping-nct-07038824\">Entrada Ekzon 45 Atlama \u2013 NCT07038824 \u2013<\/a><\/li><\/ul><\/nav><\/div>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"entrada-exon-44-skipping-nct-07037862\">Entrada Ekzon 44 Atlama \u2013 NCT07037862 \u2013<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Bu, nadir g\u00f6r\u00fclen bir genetik rahats\u0131zl\u0131k olan Duchenne kas distrofisi (DMD) hastalar\u0131nda ara\u015ft\u0131rma ilac\u0131 ENTR-601-44&#039;nin incelendi\u011fi bir \u00e7al\u0131\u015fmad\u0131r.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>\u00c7al\u0131\u015fma Ba\u015flang\u0131c\u0131 (Tahmini)<\/strong>: 2025-06-30<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Birincil Tamamlanma (Tahmini)<\/strong>: 2029-03-28<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>\u00c7al\u0131\u015fman\u0131n Tamamlanmas\u0131 (Tahmini)<\/strong>: 2029-03-28<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Kat\u0131l\u0131mc\u0131 Say\u0131s\u0131 (Tahmini)<\/strong>: 24<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Konumlar<\/strong>: Bel\u00e7ika, \u0130talya, \u0130spanya, Birle\u015fik Krall\u0131k.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>\u00c7al\u0131\u015fmaya Uygun Ya\u015flar<\/strong>: 4 Ya\u015f\u0131ndan 20 Ya\u015f\u0131na Kadar (\u00c7ocuk, Yeti\u015fkin)<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Ba\u015fl\u0131ca dahil etme ve hari\u00e7 tutma kriterleri. \u2013 <a href=\"https:\/\/clinicaltrials.gov\/study\/NCT07037862\" target=\"_blank\" rel=\"noreferrer noopener\">NCT07037862<\/a> \u2013<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"entrada-exon-45-skipping-nct-07038824\">Entrada Ekzon 45 Atlama \u2013 NCT07038824 \u2013<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Bu, nadir g\u00f6r\u00fclen bir genetik rahats\u0131zl\u0131k olan Duchenne kas distrofisi (DMD) olan kat\u0131l\u0131mc\u0131larda ara\u015ft\u0131rma ilac\u0131 ENTR-601-45&#039;nin incelendi\u011fi bir \u00e7al\u0131\u015fmad\u0131r.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>\u00c7al\u0131\u015fma Ba\u015flang\u0131c\u0131 (Tahmini)<\/strong>: 2025-09-30<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Birincil Tamamlanma (Tahmini)<\/strong>: 2029-03-01<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>\u00c7al\u0131\u015fman\u0131n Tamamlanmas\u0131 (Tahmini)<\/strong>: 2029-03-01<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Kat\u0131l\u0131mc\u0131 Say\u0131s\u0131 (Tahmini)<\/strong>: 24<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Konumlar<\/strong>: Bel\u00e7ika, \u0130talya, Hollanda, \u0130spanya, Birle\u015fik Krall\u0131k.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>\u00c7al\u0131\u015fmaya Uygun Ya\u015flar<\/strong>: 4 Ya\u015f\u0131ndan 20 Ya\u015f\u0131na Kadar (\u00c7ocuk, Yeti\u015fkin)<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Ba\u015fl\u0131ca dahil etme ve hari\u00e7 tutma kriterleri. \u2013 <a href=\"https:\/\/clinicaltrials.gov\/study\/NCT07038824\" target=\"_blank\" rel=\"noreferrer noopener\">NCT07038824<\/a> \u2013<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<p class=\"wp-block-paragraph\"><a href=\"https:\/\/dmdwarrior.com\/tr\/tag\/entrada-therapeutics\/\">Entrada Therapeutics hakk\u0131nda daha fazla bilgi edinin<\/a>.<\/p>","protected":false},"excerpt":{"rendered":"<p>Entrada Therapeutics has officially launched clinical trials in Europe for its innovative exon skipping therapies targeting Exon 44 and Exon 45\u2014marking a significant milestone in the treatment of Duchenne muscular dystrophy (DMD). These investigational therapies are designed to address specific genetic mutations in DMD patients, with the goal of restoring dystrophin production and improving clinical [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":4021,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[27],"tags":[242,233,234,84,246,319,178],"class_list":["post-4013","post","type-post","status-publish","format-standard","has-post-thumbnail","category-research","tag-clinical-trials","tag-entrada","tag-entrada-therapeutics","tag-europe","tag-exon-44-skipping-therapies","tag-exon-45-skipping-therapy","tag-exon-skipping-therapies"],"_links":{"self":[{"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/posts\/4013","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/comments?post=4013"}],"version-history":[{"count":0,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/posts\/4013\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/media\/4021"}],"wp:attachment":[{"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/media?parent=4013"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/categories?post=4013"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/tags?post=4013"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}